CDKN2A and Alzheimer disease: Furthermore, eliminating senescent astrocytes via the genetic approach and pharmacological drugs (e.g., ABT263, dasatinib, and quercetin) alleviates Aβ plaque deposition, reduces neuroinflammation, and improves cognitive function in an ex vivo model of AD and in transgenic p16-3MR mice with cognitive deficits [152, 153].